P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

Hang Quach; Meletios A Dimopoulos; Meral Beksaç; Luděk Pour; Sosana Delimpasi; Vladimir Vorobyev; Ivan Špıčka; Jakub Radocha; Paweł Robak; Kihyun Kım; Michèle Cavo; Kazuhito Suzuki; Kristin Morris; Farrah Pompilus; Jodie Wilkes; Amy Philips-Jones; Margaret Polinkovsky; Xiaoou Zhou; Giulia Fulci; Neal Sule; Brandon E. Kremer; Joanna Opalińska; María-Victoria Mateos Manteca; Suzanne Trudel

doi:10.1016/s2152-2650(24)02315-2

Article2024

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study

Vânia Hungria, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Marcelo Pitombeira de Lacerda, Gracia Aparecida-Martinez, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Rachel Rogers, Benga Kazeem, Zhaohui Wang, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos Manteca

Article2025

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Špıčka, Jakub Radocha, Paweł Robak, Kihyun Kım, Michèle Cavo, Kazuhito Suzuki, S. Yousuf Zafar, Ainslee Moore, Michael Duggan, Kristin Morris, Amy Phillips-Jones, Margaret Polinkovsky, Jayleen Grams, Ianire Garrobo-Calleja, Elisabet E. Manasanch, Brandon E. Kremer,

Article2025

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).

Meral Beksac, Hang Quach, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda, Ivan Špıčka, Marek Hus, Vera Zherebtsova, Margaret Polinkovsky, Sybil Varghese, Shing Yip Lee, Elisabet E. Manasanch, Paweł Robak, Meletios A Dimopoulos

Article2023

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.

Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos

Article2024

P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Vânia Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Jian Li, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Fotini M. Kouri, John Liboon, Chris Brawley, Eric Lewis, Gabriela Tubel, Mary Li, Astrid McKeown, Sumita Roy–Ghanta,

P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

Discussion(0)

Related publications

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.

P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)